Dantrolene

Form	20mg dantrolene powder for solution for injection
Reconstitution	➢ Add 60mL **sterile water for injection** and shake until solution dissolved ➢ Using the filter device provided, draw up the reconstituted solution into a syringe ➢ Remove the filter device before attaching the syringe to an IV cannula or giving set
Compatibility & Stability	No further dilution permitted
Administration	**Use a new filtration device with every vial of Dantrium® IV. Administer Dantrium® IV immediately upon filtration.** **Bolus intravenous injection** Management of malignant hyperthermia crisis, or neuroleptic malignant syndrome (unlicensed) ➢ Administer an initial dose: 2.5 mg/kg body weight intravenously (9 vials for a 70 kg adult). ➢ If there is no response after 5 minutes repeat a dose of 1 mg/kg. Further doses can be given every 5 minutes to a maximum of 10 mg/kg in 24 hours. ➢ The required dose to be given as a bolus intravenous injection ➢ Bolus injections may be administered rapidly (over at least one minute)
Monitoring	Monitor blood pressure, respiratory rate, pulse, temperature, pH, pCO_2, K^+
Extravasation	Dantrolene sodium has a high pH and may cause venous irritation and tissue damage in cases of extravasation. If a central venous access device is unavailable, administer via a large peripheral vein monitoring insertion site closely using a recognised phlebitis scoring tool. Re-site cannula at first signs of inflammation
Additional Information	• For a 70kg patient, if a cumulative dose of 10mg/kg is needed this will amount to approximately **36 vials** • Due to the potential for undissolved crystals/particles to appear in the re-constituted product and the subsequent potential risk of exacerbation of injection site reactions/tissue necrosis from crystals within affected vials, use of the **filtration device** when drawing up the solution is required at all times. • Each vial of Dantrium IV contains **3g mannitol** (for adjustment of isotonic solutions). This amount should be considered if mannitol is used to prevent and treat renal complications related to malignant hyperthermia. • Caution should be exercised if **hyperkalaemia** symptoms occur (muscular paralysis, ECG changes, bradycardic arrhythmias) or in cases of pre-existing hyperkalaemia (renal insufficiency, digitalis intoxication etc.), as an increase in serum potassium has been demonstrated in animal trials as a result of dantrolene. • **Liver damage** may occur during dantrolene therapy. This is dependent on the dosage and duration of therapy and may run a lethal course. • **Stock** kept in ED Antidote press, Theatres, MH Theatre

Information provided relates to Dantrium® manufactured by Norgine pharmaceuticals.

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542